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Abstract
Objectives: This study was undertaken to monitor the CD4+ lymphocyte count in individuals infected with Human
Immunodeficiency Virus (HIV) and/or co-infected with Hepatitis C Virus (HCV) and to compare this with the counts in
normal individuals in The Gambia.
Methods: Blood samples were taken from 1500 individuals referred for HIV serology at the Royal Victoria Teaching
Hospital (RVTH) following informed consent. Samples were tested for antibodies to HIV by the Murex ELISA, antibodies
to HCV by the Ortho ELISA, and CD4 counts determined by the Dynalimmunomagnetic cell isolation method
Results: Of  the 1500 patients screened for HIV and HCV antibodies, 6.7%  (101/1500) were infected with HIV, 0.6 % (9/
1500) were co-infected with HCV and 1.5 %( 22/1500) were infected with HCV alone. Almost half  (44.6%; 25/56) of  HIV-
1 infected patients had a CD4+ lymphocyte count at diagnosis of 200 cells/µl or less as compared to 41.7 %( 10/24) of
HIV-2 and 75% (6/8) of  HIV-D infected patients. The rate of  CD4 decline was higher among HIV/ HCV co-infected
persons than individuals infected with HIV or HCV. The rate of  decline was higher among men than women. These
differences did not reach statistical significance due in large part to the small number of participants who completed the
programme. The CD4+ lymphocyte count of apparently healthy Gambian male and females was 489 cells/µl and 496 cells/
µl respectively. This rate is lower than that reported for Caucasians, but in agreement with the global range.
Conclusion: A significant progressive decline in CD4+ lymphocyte count was observed among the female control group
who were negative for HIV and HCV. This finding is unclear and calls for a longitudinal study involving a cohort of  women
in this region.
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Introduction
Measuring the CD4+ lymphocytes count remains
the most effective means of evaluating of the clinical
prognosis of patients infected with Human
Immunodeficiency Virus (HIV)1. This measurement
has been universally accepted as a uniform means
for the clinical staging of patients infected with HIV
and those progressing to AIDS2 and for the
determination of  the commencement of  anti-
retroviral therapy and for monitoring response to
it3. Racial differences in the rate of CD4+
lymphocyte decline in HIV infected men have been
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reported4. Such differences have not been reported
in HIV-2 or HIV2/HCV co-infected persons.
Studies of the  trends in the CD4+
lymphocyte count of HIV and HIV/HCV infected
patients among different demographic groups can
provide insight into the natural history of HIV1,5 and
HIV/HCV co-infection6,7  and potentially influence
the development of  effective intervention
programmes. However, few data are available on
the CD4+ lymphocyte values of HIV infected or
apparently healthy persons in most developing
countries. In The Gambia, there is a paucity of
information on CD4+ lymphocyte counts in the
healthy Gambian population for establishing a
normal reference value. The present study which
forms part of  work carried out on HIV and HCV
co-infection in the Gambia was aimed at obtaining
base-line data of CD4+ counts in apparently healthy
individuals (pregnant women and blood donors) and
African Health Sciences Vol 9 No 3 September 2009 131
those  infected with HIV  and/or Hepatitis C virus
and to monitor trends in these groups.
Methods
Study population and sample collection
A total of 1500 people age 11 months to 76 years
referred for HIV serology at the Royal Victoria
Teaching Hospital, Banjul, The Gambia between the
months of July and December 2002 were counseled
on a one to one basis. Following informed consent,
10 ml of venous blood was drawn from each
participant. Samples from pregnant women were
collected during their registration visit to the antenatal
clinic irrespective of  their trimester of  pregnancy. 2
ml of each blood sample was dispensed into an
EDTA container for CD4+ count. The remaining
was centrifuged and the serum separated and frozen
in two aliquots. One aliquot was preserved at 20oC
for short-term use and the other at 70oC. No
patient was aware of his HIV status prior to the
visit to the hospital. Data on patients demographic
characteristics and behavioural factors were obtained
in a one to one personal interview.
HIV Serology
Stored sera were screened every two weeks for HIV
antibodies using Enzyme linked immunosorbent
assay (ELISA) (8) kits Murex HIV1,2,0 (Murex
Biotech, UK) following the manufacturers
instruction.  All samples reactive to Murex HIV-1.2,
0 were further tested using PEPTI-LAV 1-2 (Sanofi,
France) for confirmation of  the presence of
antibodies to HIV and for differentiation into
subtypes following the manufacturers instructions.
Samples reactive to Murex HIV 1, 2, 0 but
un-reactive to PEPTI- LAV 1-2 were considered
non-reactive. Those reactive to Murex HIV 1,2,0 and
reactive to PEPTI LAV 1-2 either on the HIV-1 band
or HIV-2 band or on both bands were confirmed
to have antibodies against HIV. The test was repeated
for all the samples reactive to Murex HIV 1, 2, 0.
HCV serology
Ortho HCV Version 3.0 Enzyme Immunoassay
(EIA) Test Kit (Ortho Clinical Diagnostics, USA)
was employed for the detection of  anti-HCV.  HCV
Screening was carried out in batches on weekly basis
or within 10 days of collection using refrigerated
aliquots. The test procedures recommended by the
manufacturers was adhered to.
CD4 enumeration
The CD4+ count of every sample collected was determined
using the immunomagnetic cell isolation method
(Dynal A. S., Oslo, Norway) within four hours of
collection following the manufacturers instruction.
The CD4 count taken at the diagnosis of the
individual HIV/HCV state was defined as CD4dx.
 The principle of the test is based on the
coating of Dynalbeads with monoclonal antibodies,
which serves as a solid phase for the direct isolation
of CD4+ lymphocytes from blood. Accurate
measurement is facilitated by the ability of
Dynalbeads CD14 and Neodymium-iron-boron
magnet (MPC-Q) to deplete monocytes, which may
also express CD4+ antigen.
Statistical analyses of data
Chi-square and Fisher exact tests were employed to
test the association between variables, while simple
and multiple regression analysis were used to examine
the influence of selected covariates on CD4+
lymphocyte counts.
Results
Demographic Characteristics of participants
The participants were aged 11 months to 76 years
and all had no previous knowledge of their HIV or
HCV status. There overall mean age was 30.2 years;
31.9 years for the males and 28.7 years for females.
Females accounted for 61.9 percent (928/1500) of
the participants, while males accounted for 38.1 %
(572/1500) of  the participants. Over 70 percent
(693/928) of the female participants were antenatal
cases. Other participants include blood donors
(30.7%, 460/1500), in and out patients with varying
diagnoses (19.3%, 290/1500), people attending
family planning clinic (1.9%, 28/1500) and medical
examination for employment and educational
purposes (1.9%, 29/1500).
Identification of Case and control groups
A total of 101 HIV infected patients were detected,
of  whom 9 were co-infected with HCV, and 22
patients were infected with HCV alone. The
remainders were both HIV and HCV seronegative.
A summary of the CD4 count of these patients in
relation to their HIV and HCV status is presented in
table 1 below. These patients formed the basis for
the selection of  the case and control groups.
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Table 1:  CD4 (CD4dx) counts of  HIV and HIV/HCV co-infected persons at diagnosis of  HIV/
HCV status (Figures are number in %)
Viral infection Sex <200 CD4+ Lymphocyte >500
Count (cells/µl)
 200-499
HIV-1 Male 3   (42.9) 2   (28.6) 2   (28.6)
Female 22  (44.9) 24  (50.0) 3    (6.1)
HIV-2 Male 4   (57.1) 2   (28.6) 1   (14.3)
Female 6   (35.3) 5   (29.4) 6   (35.3)
HIV-D Male 1   (100) 0 0
Female 5   (71.4) 2   (28.6) 0
HIV/HCV Male 2   (28.6) 5   (62.5) 0
Female 1   (50.0) 1   (50.0) 0
Category 1 (HIV seropositive subjects)
This group was made up of all the anti-HIV
seropositive persons. Nine were co-infected with
HCV and were classified under a different category;
four were lost to follow-up and one declined
follow-up after post-test counseling. The remaining
eighty-seven patients were listed for participation in
this category. The details of  the 87 patients were as
follows: 72 females including 49 HIV-1 infected with
an age range of 3 years to 47 years (mean age-26.5
years), 17 HIV-2 infected patients with an age range
of 20- 26 years (mean age-28.6 years) and 6 infected
with HIV-1 and HIV-2 (HIV-D) aged 16-36 years
(mean age-24.9 years). Fifteen males included seven
HIV-1 patients with an age range of  19-67 years
(mean age-35.1), seven infected with HIV-2, ranging
from 20-58 years in age (mean age 35.3 years and a
67 years old man infected with HIV-1 and HIV-2
(HIV-D). 
Category 2 (HIV and HCV coinfected persons)
The second group were patients with HIV and HCV
co-infection, seven men in the age range of 26 58
years (Mean age: 39.1 years) and two women aged
32 and 33 years (Mean age- 31.5 years). Six of the
men had HIV-1/HCV co-infection and one HIV-
2/HCV co-infection. Two women, one in her
second trimester of pregnancy as per time of
enrolment had HIV-1 and HCV co-infection and
the other, a full-time housewife, had HIV-2/HCV
co-infection. 
Category 3 (Negative control group)
The third group consists of a total of 288 persons
enrolled as a negative group. This group was made
up of  222 women confirmed as HIV and HCV
seronegative and selected on basis of age to match
the 72 HIV positive women, 66 men confirmed as
HIV and HCV seronegative selected on basis of
age to match the 22 HIV positive men.
Follow-up study
Follow-up blood samples were collected every six
months from all cases and control subjects who kept
the appointment. Thus a total of three samples were
collected from each participant in the months of
June 2003, December 2003 and June 2004.
Participants who did not keep the appointment
within one month of the schedule date were
excluded from further participation.  Similarly
participants with counts below 250 cells/µl were
referred for antiretroviral therapy (ART) and
excluded from the programme. The test procedures
for the follow-up CD4 count, HIV and HCV tests
were the same as previously enumerated.
CD4+ lymphocyte count trends in HIV1
Infected patients
The mean CD4+ lymphocyte count of males and
females as per the diagnoses of their HIV status was
375 cells/µl and 291 cells/µl respectively.
Only 4 out of the 7 men (57.1%) and
25(51.0%) women participated in the first round of
the followup test six months later.   The mean CD4+
lymphocyte count for the 4 male participants was
464 cells/µl   and 339 cells/µl   for the 25 females.
During the second round of the follow-up test 12
months later only three males (42.9%) and 18(36.3%)
females participated.  The mean CD4+ count of
these was 328 cells/ and 303 cells/ for male and
females respectively.  There was a 29.3% and 10.6%
decline in the mean CD4+ count of the male and
female participants over the 6-month interval.
Similarly, the last round of  the follow-up test had
only 2 male and 10 female participants and their mean
CD4+ count was 316 cells/µl  and 285 cells/µl   for
male and females respectively.  The cumulative decline
in CD4+ of the participants who fully completed
the programme was 43.2% and 44.4% for male
versus female respectively. A highly significant
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(p<0.0001) was found between CD4dx and  the
declining CD4 trends  when CD4dx was regressed
against, the first, second and third CD4 counts
however, no such association was found between
CD4 counts and age or sex due in large part to the
small number of participants who completed the
programme.
CD4+ trends in HIV 2 infected persons
Unlike in HIV  1 infection the means CD4+dx
count for HIV  2 infected females were
comparatively higher than their male counterparts
(354 cells/µl versus 287 cells/µl) at the time of
diagnosis.  The 3 males and 10 females who
participated in the first round of the follow-up test
after the withdrawal of participants with counts of
below 250 cells/µl had a mean count of 345 cells/
µl   and 403 cells/µl  respectively.  The second round
of the follow up test had one male and seven
females participants. The mean CD4+ count of  the
female participants was 400 cells/µl.  The last round
of follow-up test had a total of six participants made
up of five females and a male.  The mean CD4+
count of the females was 355 cells/µl.
The rate of decline in CD4+ lymphocyte
among HIV-2 infected males was slower than their
HIV- 1 counterparts; however, this difference was
not consistent among the females. There was a highly
significant association between CD4dx and the
decline in CD4 counts, however, this association was
not found for age and sex due in large part to the
small number of participants who completed the
programme.
CD4+ trends in HIV-D infected patients
The mean CD4+ count of  all the HIV-D infected
persons as per the time of diagnosis of their HIV
status was 232 cells/µl.  The three participants in the
first round of the follow-up test had a mean count
of 242 cells/µl.  The only participant in the second
and final rounds of the follow-up tests had a count
of  398 cells/µl and 258 cells/µl cells respectively,
showing 35.2% decline in CD4+ count in an interval
of  6 months. There was a highly significant
association between CD4dx and the decline in CD4
counts, however, this association was not found for
age and sex due in large part to the small number of
participants who completed the programme.
CD4+ trends in HIV/HCV co-infected persons
The mean CD4+ count for the HIV/HCV
participants as per the time of diagnosis of their
status was 306 cells/µl  while the HIV-2 /HCV
participant had a mean count of 365 cells/µl .  The
first round of  the follow-up had only 6 participants.
This comprised of  4 HIV-1/HCV and two HIV-
2/HCV participants with a mean count of 320 cells/
µl and 297 cells/µl   respectively.  The second and
final follow-up tests had only two male participants
who were HIV-1/HCV infected their mean CD4+
count was 272 cells/µl   and 171 cells/µl   respectively
sharing a decline of 37.1%.  No HCV
seroconversion was recorded among the participants
throughout the follow-up period.
CD4+ lymphocyte trend among HIV and HCV
seronegative control subject
The mean CD4 lymphocyte count of the 222 female
participants as per the time of    diagnosis of their
HIV and HCV status was 496 cells/ µl.  Their mean
age was 28.6 years.  The 220 participants who were
tested during the first round of the follow-up test
had a mean count of 503 cells/µl The second round
had 216 participants who recorded a mean count
of 499 cells/µl   revealing a 0.8% decrease in count
while the last round of the follow up test had only
214 participants with a mean CD4 count of 491
cells/µl showing a downward decline of 0.2%. This
declining trend in CD4 was statistically significant.
The 66 male control groups had a mean
age of 35.8 as per the time of enrolment and a mean
CD4+ count of 489 cells/ µl.  The first follow-up
test had 66 participants with a mean count of 492.
The second and final follow-up test had 60
participants with a mean count of 509 and 513 cells/
µl  respectively. The counts showed a 3.5% and 0.8%
increase in CD4+ count after 6 months and 12
months intervals. This trend in CD4 was not
statistically significant.
HIV-seroconversion
Four cases of  HIV seroconversion was recorded
among the 288 negative control subjects.  There were
made up of 3 women and a man.  These persons
were excluded from further participation in the study.
No HCV seroconversion was recorded among all
the control participants throughout the duration of
the follow-up test period.
Discussion
The finding of a comparatively higher number of
females than   males infected with HIV at a younger
age than their male counterparts in this study is line
with the epidemiology of  HIV in most sub-Sahara
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Africa countries 9. This pattern has been attributed
to the predominantly heterosexual mode of
transmission of the virus in the region10,11
The mean CD4+ determined among the
adult male and female HIV and HCV seronegative
persons employed as control groups in this study is
within the globally acceptable range12 ; however, this
rate is comparatively below that reported for
Caucasians. Several studies emanating from non-
Caucasians population have reported similar lower
CD4 count than reported for Caucasians 13.  This
finding makes the need for the employment of the
CD4 of the Gambian population as a yardstick for
the clinical staging and evaluation of her HIV/AIDS
patients.
The finding of a comparatively larger
population of HIV  1 infected woman presented
with a lower CD4+ count their male counterparts,
while HIV-2 infected  females  had  a higher count
the males  as per the time of diagnosis of their HIV
status of in this study cannot be  fully explained.
Kilaru et al, 14 in a study conducted in Barbados found
a comparatively higher proportion of women
infected with HIV with a higher level of CD4 count
as per the time of the diagnosis of their HIV status
than their male counter parts. Generally, women are
associated with higher CD4+ counts than their male
counterparts and sex differences in the  decline in
CD4+ count has  not  been found to be influenced
by gender,  except during  the close to the AIDS
phase  when the decline become enhanced in men15.
Although in this study this difference was not
significant statistically (p>0.05) it could be due to
the stage of infection of the participants or other
inherent factors such as environment, race among
others that influences CD4 count16.
The finding   in this study of a persistent
decline in the   CD4 count of apparently healthy
(HIV and HCV seronegative) women over the 18
months period is unclear. Although the rate of  decline
was quite low it was statistically significant and   was
not seen among the males.  A possible explanation
for this is that in addition to the numerous factors
which may influence CD4 count17  most especially
among women,  the  duration of the follow-up
period was probably too short for  a  coherent
conclusion to be made. Furthermore, more than 90%
of the women employed as control group in this
study were either pregnant women or lactating
mothers. The contributing role of  reproductive
hormones such as chorionic gonadotropin (CG),
estradiol and progesterone, and their physiological
combinations which are expressed during pregnancy
and postpartum period on CD4 count have not been
evaluated in this study. Little or no data exist on the
influence of  reproductive hormones on CD4 count
in apparently healthy women. The few available
studies have focused on HIV-infected with   varying
findings18,19 . There is therefore need for a more
elaborate longitidutinal study employing a cohort of
pregnant and non-pregnant women to validify this
finding.
In this study, the rate of  decline in CD4+
varied proportionally according to the type of HIV
infection. Although this variation was not significantly
associated with the type of  HIV, the finding of
persons with HIV and HCV coinfection with the
highest level of decline within the 18 months period
as compared to persons infected with HIV alone
and HIV-D infected person with a higher decline
than HIV1 or HIV-2 infected persons may be
suggestive of  the degree of  severity associated with
these infections20,21 .
Some studies have advanced reasons for the
accelerated HCV progression in HIV coinfected
persons. One study showed HIV/HCV coinfected
persons with CD4 count of less than 500 cells/µl
had  less immune response to HCV compared to
persons with   counts greater than 500 cells/µl, while
individuals with count less than 200 cells/µl had
worse response20.
In this study no individual coinfected with
HIV and HCV had a CD4 count above 500 cells/
µl at diagnosis (CD4dx). CD4+ decline was
progressively higher in HIV-1/HCV infected
individual than in HIV-2/HCV infected person.
Similarly the rate of decline was higher in coinfected
individuals than in persons infected with HIV or
HCV alone however; these differences did not reach
statistical significance. The accelerated decline in CD4
count observed in these individuals as compared to
those infected with HIV or HCV alone may therefore
be line with these reports. This assertion is   further
supported by studies that provided evidence of less
stimulation of CD8 HCV cells that target HCV thus
contributing to quicker HCV progression in HIV
infected individuals. This finding underscores the need
for early diagnosis of people at risk of HIV/HCV
coinfection and supports reports suggesting   the
commencement of therapy at a comparatively higher
CD4 count than in coinfected persons.
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Conclusions and Recommendations
This study revealed that more women than men were
proportionately infected with HIV at a comparatively
lower age than the men and that this sex and age
differences was significant. The determined CD4
count of apparently healthy Gambian male and
females was 489 cells/µl   and 496 cells/µl
respectively.  This rates, though lower than that
reported for Caucasians is within the   normal range.
It also shows that the mean CD4+ count as per time
of the diagnosis of the HIV status of the participants
was 375 cells/µl   and 291 cells/µl    respectively for
HIV 1 infected male and female participants and
354 cells/µl   versus 287 cells/µl   for male and
female HIV  2 infected participants.  While
participants infected with HIV D had a mean count
of 232 cells/µl, while HIV and HCV co-infected
persons who were predominantly males had counts
of 306 cells/µl   as per the time of diagnosis of
their status.  The study reveals a more gradual decline
in CD4+ among the females than the males.  This
study revealed that the CD4+ count of infected
persons was directly proportional to the severity of
type of HIV infections, while a significant progressive
decline in CD4 count was observed among the
female control group. This finding is unclear and
calls for a longitudinal study involving a cohort of
pregnant and non- pregnant women. These
observations have important implications in clinical
staging and management of HIV/AIDS   in the
Gambia.
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